Home | Add Company | Subscribe | Search | Contact





Add Company

Your company can benefit from enhanced listings. Questions? Read our FAQ first.


Personalized notification service and newsletter info

Subscribe (free) to get notified of new additions.


Learn more About us and about our Services


Contact us

New service, packaging/unit dose

HEALTHPOINT Introduces Unit Doses of Panafil®, Accuzyme®

Concerns: service, packaging/unit dose
Released on: 28-Feb-2003

Pharmaceutical form and dosage: 6g unit doses Ointment

Packaging: 30g tubes, 6g unit dose tubes

Active substances / mechanism: Panafil Ointment: papain, urea and chlorophyllin copper complex sodium in a hydrophilic base.

Accuzyme: papain plus urea stimulates the digestive potency, allowing for debridement of necrotic tissue and liquefication of pus in lesions.


- Curative
- Drug delivery
- Pharmaceuticals / Therapeutics
- Prescription drugs (Rx)
- Preventive
- Technology

Therapeutic target:

- Aging
- Alzheimer's Disease
- Cancer
- Dermatology
- Diabetes
- Epidemiology
- Gastrointestinal
- Geriatrics
- Infectious Diseases
- Men's Health
- Oncology
- Orthopedics
- Pain
- Surgery
- Transplant
- Urology
- Women's Health

Concerns the following market:
- United States of America

See also:

Company Profile: Healthpoint, Ltd., a DFB Pharmaceuticals Company
United States of America

Contact for this news release: Jay Nisbet

Or check this company's:

Full Description:
(Fort Worth, TX, USA) — HEALTHPOINT, Ltd., a Texas, USA-based market leader in tissue management, surgical, and dermatology products, has introduced the first unit dose packaging of its popular prescription ointments Panafil® and Accuzyme®---in bar coded six-gram units to complement the standard 30 gram tubes.

Accuzyme is an enzymatic debriding ointment used to treat necrotic wounds, pressure ulcers and burns by removing dead tissue without harming living tissue. Panafil is a healing, debriding, and deodorizing ointment that promotes healing, controls inflammation and reduces wound odors.

“Chronic wounds affect millions of people every day,” said Richard Rudman, wound management marketing director for HEALTHPOINT. “These new six gram unit doses are a safe, easy option for first time applications and for situations that require less therapy.”

Unit doses for Panafil® and Accuzyme® will be available February 1 across the United States. Panafil and Accuzyme are generally well tolerated, however upon application a small percentage of patients may experience a brief stinging sensation.

Since its inception in 1992, HEALTHPOINT has established an international presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for the tissue management, dermatology, and surgical. An aggressive research and development effort has brought HEALTHPOINT’s unique technologies to the market, setting the pace for its highly trained U.S. field sales organization. HEALTHPOINT, with over 250 employees, is a DFB Pharmaceuticals, Inc. affiliate company.

DFB provides technology-driven products, outsourcing services and licensing opportunities to the healthcare industry worldwide through its affiliate companies, contract partners, and branded marketing organizations.

HEALTHPOINT headquarters are in Fort Worth, with an additional office in Canada. Visit the web site at www.HEALTHPOINT.com.


  Contact for this news release: Jay Nisbet

Suggestion box | Disclaimer | Privacy Policy | Rules & Regulations
Copyright© Cofidei, Inc. - Page last modified: 28-Feb-2003.

Home | Add Company | Subscribe to Newsletter | Search Companies | Search Offers | Power search